Please login to the form below

Not currently logged in
Email:
Password:

acute heart failure

This page shows the latest acute heart failure news and features for those working in and with pharma, biotech and healthcare.

Novartis and Bayer among backers for European big data project

Novartis and Bayer among backers for European big data project

Novartis and Bayer among backers for European big data project. The IMI's BigData@Heart programme will target cardiovascular research. ... Its overarching aim is to improve patient outcomes and reduce the burden on society of atrial fibrillation (AF),

Latest news

  • New drugs can't keep Novartis sales on the up New drugs can't keep Novartis sales on the up

    The continued glacial growth of Novartis' heart failure hope Entresto weighed on its first-quarter results as sales declined on generic competition. ... year. A decision to drop development of acute heart failure drug serelaxin (RLX030) also pegged back

  • What future for serelaxin after phase III miss? What future for serelaxin after phase III miss?

    What future for serelaxin after phase III miss? Novartis' acute heart failure therapy misses two main endpoints. ... The failure of Novartis' acute heart failure therapy serelaxin to hit its objectives in a second phase III trial is somewhat embarrassing

  • Novartis boosts cardiovascular pipeline with $1bn Ionis deal Novartis boosts cardiovascular pipeline with $1bn Ionis deal

    The company launched first-in-class chronic heart failure therapy Entresto (sacubitril and valsartan) in 2015 and is hoping to re-file acute heart failure candidate serelaxin (RLX030) this year. ... Aside from the new additions, Novartis late-stage

  • Amgen agrees to take Cytokinetics' heart failure drug into phase III Amgen agrees to take Cytokinetics' heart failure drug into phase III

    Amgen has finally decided to push a novel drug candidate for chronic heart failure into a full phase III testing programme. ... Crucially, no safety signal emerged in the COSMIC-HF study. An earlier trial of omecamtiv mecarbil in acute heart failure -

  • Novartis says Cosentyx is 'outpacing competitors' Novartis says Cosentyx is 'outpacing competitors'

    The Swiss group is meeting with analysts and investors in Basel today to discuss its strategy for the next few years and update on progress with Cosentyx (secukinumab), heart failure therapy ... These include RLX030 (serelaxin) for acute heart failure,

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    2, 700. Cardioxyl Pharmaceuticals. Bristol-Myers Squibb. Acquisition - company. Lead asset: p2 CXL-1427, nitroxyl (HNO) donor (prodrug) - iv treatment for acute decompensated heart failure (ADHF). ... 379. Cellectis. Servier. Option exercise. UCART19, CAR

  • Pharma deals during October 2013 Pharma deals during October 2013

    80. Celladon. Mydicar gene therapy for heart failure (phase IIb). 75. ... 75. Trevena. TRV027, GPCR biased ligand for acute heart failure (phase II).

  • Pharma deals during July 2013 Pharma deals during July 2013

    Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Omecamtiv mecarbil is currently in phase II trials

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    TRV027 phase 2 acute heart failure $30m equity. 460. Omthera/ AstraZeneca. ... Adasuve approved for acute agitation. 235. EKOS/ BTG. Company acquisition. Device for treating blood clots.

  • Pharma deals during May 2013 Pharma deals during May 2013

    The deals that fall into this category are: Forest's $460m option to license a phase II acute heart failure treatment from Trevena; Merck's $430m licence of diabetes type 2 ... In effect, governments and NGOs are stepping in to correct the 'market failure

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics